Sensius

About:

A medical device company changing the cancer treatment balance in survivorship and quality of life: improving both

Website: https://www.sensiusthermotherapy.com

Top Investors: European Innovation Council, EASME - EU Executive Agency for SMEs, UNIIQ, Undisclosed Individual investors

Description:

Sensius fundamentally changes the risk-reward balance when treating cancer. Addition of Sensius’ thermotherapy to cancer treatment improves both outcome and quality of life, where mainstay treatments (radio- and chemotherapy) are inherently toxic. Sensius is a medical device company that has built a bespoke cancer therapy device using proprietary thermal technology and software. The device is designed by clinicians who use their skills and experience to craft unique thermal collars to treat initially head and neck cancer. Seventy patients have been treated with the device. A study demonstrated 81.8% of the patients having a complete response at 12 weeks following radiotherapy. The Company is now moving to build a CE marked device: already 20 interested parties are intending to purchase the device as soon as it is CE/FDA-marked. A roadmap for other cancer treatments is available.

Total Funding Amount:

12.7M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Rotterdam, Zuid-Holland, The Netherlands

Founded Date:

2015-04-02

Contact Email:

info(AT)sensiusthermotherapy.com

Founders:

Gerard van Rhoon, Maarten Paulides, Paul van den Biggelaar, Peter Van Paassen

Number of Employees:

1-10

Last Funding Date:

2023-02-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai